The Pipeline

Our lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist. We are advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and advanced prostate cancer. Takeda is currently conducting two Phase 3 trials evaluating relugolix in Japan for the treatment of uterine fibroid-related pain and heavy menstrual bleeding, respectively.

Our second product candidate is MVT-602, an oligopeptide kisspeptin analog. We plan to develop MVT-602 for the treatment of female infertility as part of assisted reproduction.

 
Compound Indication Phase 1 Phase 2 Phase 3
Relugolix
Uterine Fibroids - Heavy Menstrual Bleeding Phase 2 Complete
Endometriosis - Pain Phase 2 Complete
Advanced Prostate Cancer Phase 2 Complete
MVT-602
Female Infertility as Part of Assisted Reproduction Entering Phase 1
Relugolix - Japanese Development (Takeda)
Uterine Fibroids - Heavy Menstrual Bleeding Currently in Phase 3
Uterine Fibroids - Pain Currently in Phase 3